← Back to Blog
Medical Tourism

Shenzhen Medical Tourism: Three International Hospitals, a Three-Day Workup, and Solid-Tumor CAR-T

OriEast Editorial Team•2026-11-20

Quick Answer

Use this page to quickly understand what kinds of topics we cover, who the content is most useful for, and where to go next.

Main topics
Medical Tourism
Best for
APEC coverage of Shenzhen's inbound "medical travel" names three hospitals, gives patient-origin counts and a three-day diagnostic turnaround — and one therapy that is not yet approved in the US.
Best next step
Explore Cancer Treatment in China

Need help applying this to your own case?

OriEast can help turn what you learned here into the right next step for hospital choice, records preparation, or travel planning.

How OriEast helps

We help international patients move from reading and research to real medical coordination in China.

  • ✓Clarify whether this topic is relevant to your case or travel plan
  • ✓Shortlist the right hospital, service, or specialist pathway
  • ✓Review records and reduce planning mistakes before booking
  • ✓Support hospital coordination, travel timing, and next-step questions

Your records are only shared as needed to coordinate planning and specialist review.

APEC season has made Shenzhen an unlikely case study in cross-border healthcare. A report published in Ta Kung Pao on 13 November 2026 described what its journalists called overseas patients coming to the city for "medical travel," and — unusually for this genre — it attached specifics to the claim: named hospitals, counts of patient nationalities, a stated diagnostic turnaround, and one therapy that China's regulator approved before the United States did. For anyone weighing whether to fly to China for treatment, those specifics are more useful than a savings percentage, because they are the things you can verify, request in writing, and build an itinerary around.

This article separates three questions that usually get blurred together: which Shenzhen facilities actually accept international patients, how long a workup realistically takes, and whether solid-tumor CAR-T is a legitimate reason to choose this city over somewhere closer to home.

What the APEC coverage puts on the record

The report's factual spine, as published here:

  • By September 2026, the international medical centre of The University of Hong Kong–Shenzhen Hospital (港大深圳醫院國際醫療中心) had received patients from 136 countries and regions, with throughput 13.5% above 2025.
  • Shenzhen Hospital of Southern Medical University (南方醫科大學深圳醫院) covers 68 countries and regions, handles about 22,000 visits a year from Hong Kong, Macao, Taiwan and overseas patients, of whom roughly 2,000 are foreign nationals.
  • At 深圳新風和睦家醫院, a private facility, foreign patients account for about one tenth of the patient mix.
  • Foreign patients were described as completing endoscopy, imaging and pathology review — a full diagnostic workup — within three days of admission. In one case an adenoma roughly the size of a coin was resected endoscopically 12 cm from the anus, in a procedure the report puts at under 20 minutes.
  • In June 2026 China's National Medical Products Administration approved what the report calls the world's first CAR-T cell therapy aimed at solid tumours, a class of treatment not yet approved in the United States; American patients travelled to Shenzhen to receive it, at total cost the report says is far below US inpatient treatment.

One nuance worth holding onto: most of that "overseas" volume is Greater China, not long-haul. About 2,000 foreign nationals out of 22,000 visits means the international desk at a Shenzhen public hospital is experienced, but not a factory line for transatlantic patients. Plan accordingly.

The three Shenzhen centers named in the report

FacilityWhat the report attributes to itPractical read for a foreign patient
The University of Hong Kong–Shenzhen Hospital, international medical centrePatients from 136 countries and regions; volume +13.5% vs 2025The broadest documented foreign-patient footprint of the three; a joint-venture governance model that leans on Hong Kong-era service conventions
Shenzhen Hospital of Southern Medical University68 countries and regions; ~22,000 annual cross-border visits, ~2,000 foreign nationalsLarge public tertiary hospital with high subspecialty volume; expect an international desk rather than a fully English hospital
深圳新風和睦家醫院 (Shenzhen Xinfeng / 和睦家-branded private hospital)Foreign patients roughly 10% of the patient mixPrivate model where English capability and appointment control are the product; access to advanced inpatient programs depends on referral

Directory listings and current department-level English capability are on our hospitals page. Do not assume that because one department has an international desk, the oncology ward you actually need does too — that is a question for the specific service line.

A three-day diagnostic timeline, as reported

The turnaround figure is the most actionable thing in the report, because a short workup is what makes a single trip viable instead of two. Here is how it maps onto a real itinerary, and where it usually breaks.

StageWhat the report describesWhat to confirm before you fly
Pre-arrivalNot specifiedWhether the hospital will accept overseas records in advance and pre-book endoscopy and imaging slots
Admission, Day 1Start of the three-day windowFasting rules, anticoagulant hold period, contrast-allergy screening, renal function needed before CT with contrast
Days 1–2Endoscopy and imaging completedWhether sedation endoscopy can be same-day, and who escorts you afterwards (most facilities require one)
Days 2–3Pathology review completedWhether your outside slides or paraffin blocks physically arrived; review cannot start without them
Day 3 onwardResults assembled for a treatment discussionWhether a multidisciplinary opinion is scheduled that week or the following one

The 20-minute endoscopic resection is a fair illustration of why patients accept the logistics: in several health systems a small rectal adenoma found on screening colonoscopy can be referred for a scheduled interval of weeks. Speed of scheduling, not technical rarity, is what Shenzhen is selling here. Our health checkups guide covers the screening-first version of the same trip.

Solid-tumor CAR-T is the one hard reason to fly to Shenzhen

What is approved, and what is not

Regulatory sequencing created the opening. If China's regulator licensed a solid-tumor CAR-T product in June 2026 and the equivalent class remains unapproved in the US, then for some tumour types the question facing a patient is not "where is it cheaper" but "where is it legal to receive it at all." That is a genuinely different decision, and it is the strongest single argument in this article. Details of what has since been approved, and for which indications, are on our CAR-T therapy in China service page and in CAR-T therapy in China: cost and access; the broader oncology pathway is described under cancer treatment in China.

What a realistic pathway involves

Cell therapy is not a single appointment. A candidate usually needs: confirmation of diagnosis and prior treatment history; disease that is measurable and at a stage where the team judges benefit outweighs toxicity; apheresis to collect cells; bridging therapy while the product is manufactured; lymphodepleting chemotherapy; infusion; and inpatient monitoring for cytokine release syndrome and neurological events, which is exactly why the report frames the comparison against US inpatient cost. Then follow-up, which is the part most itineraries forget.

Where the honest uncertainty sits

The report does not name the product, the indication, the hospital that administered it, or the eligibility criteria. Do not let a marketing summary fill those gaps. Whether you qualify, and whether a Shenzhen centre can lawfully treat you and still hand you back to your local oncologist, is decided by reviewing your actual pathology and molecular data — and any specific treatment plan must be assessed in person by a licensed physician.

What "much cheaper than the US" does and does not tell you

No rate card appears in the source material, so we will not invent one. What determines your bill is knowable in advance, and each line is negotiable in the sense that you can choose it or decline it.

Cost lineWhat actually drives itWhat to ask for in writing
Consultation and multidisciplinary reviewNumber of specialists, whether overseas records must be re-derivedFixed fee, and whether a second opinion is included
Endoscopy and imagingSedation, contrast, number of sequences, ward vs day-casePer-procedure quote including facility fee
Inpatient daysThis dominates a CAR-T or post-resection billExpected length of stay by ward type, and the daily rate
Cell therapy itselfProduct, manufacturing, apheresis, lymphodepletion, rescue careA staged quotation, itemised by phase
Language and escortProfessional medical interpreting vs ad hocWhether the hospital provides it, at what hourly rate
Follow-up after you leaveTests repeated locally vs flown back forA named follow-up schedule and who reads the results

Treat all of it as subject to the hospital's own written quotation. Insurance is the least settled line: reimbursement for an unlicensed product received abroad is rarely automatic, and our China medical visa guide and the complete medical tourism guide to China cover the documentation your insurer will ask for.

How to prepare: visa, records, sequencing

Three sequencing mistakes cost patients the most time here. First, arriving before the hospital has agreed to see you: the three-day workup assumes slots were reserved. Second, sending a PDF summary instead of the source material — imaging should come as a DICOM disc or download link, and pathology review generally needs the original slides or blocks released by your own lab. Third, planning the trip backwards from a drug approval date rather than forwards from a recovery window; cell therapy and any sedated or surgical procedure need a buffer before you can fly, and long-haul travel immediately after treatment is a medical decision, not a booking one.

Who Shenzhen suits — and when it does not

This city makes sense when one of three things is true: you need a diagnostic answer quickly and your local system cannot give it inside a month; you need a specific capability the report illustrates, such as same-admission endoscopy plus pathology review; or your disease falls inside a program approved in China and not yet available to you at home. It is a poor fit when what you need is ongoing, reimbursable, locally supervised care close to family, or when your condition is unstable enough that a flight is the riskiest part of the plan.

Get a written plan before you book a flight

OriEast can arrange translation, hospital appointments and day-to-day coordination in Shenzhen, and — more importantly — can put your records in front of the relevant department before you commit to travel, so that the answer you get is a schedule and an itemized quotation rather than a range. Start with a case evaluation, or send us an inquiry and we will tell you plainly if Shenzhen is the wrong city for your situation.

Next step

If this topic is relevant to your treatment or travel plan, these pages are the best next place to continue.